Search
for

    Learn

    5 / 801 results

      learn Tofacitinib

      a JAK inhibitor for alopecia areata and other autoimmune conditions

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects

      learn Minoxidil

      An essential vasodilator with some anti-androgenic effects, has excellent safety record

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Fevipiprant 2019!

       15 upvotes 9 years ago
      The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

      community Has anyone else seen this encouraging verteporfin case study?

      in Progress Pictures  35 upvotes 2 years ago
      The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

      community Upcoming Setipiprant clinical trials hint at systemic daily dosage

       22 upvotes 10 years ago
      The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

      community I’m taking Veradermics VDPHL01 - AMA

      in Treatment  174 upvotes 2 months ago
      A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

      community Veradermics VDPHL01: why isn’t anyone talking about it?

      in Treatment  42 upvotes 1 year ago
      Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.